RE: RE: Worth Repeating - ReplyHey lightweight, you did not include my complete 3/24 reply to you so I pasted it below. Can you talk with JJG001 and explain why my health will impact the market and advanced my trading strategy. You two seem fixated on my health. My strategy is quite simple. I bought the bulk of my holdings of ONC years ago. I am buying more on margin. I have made money to date and the amount will be peanuts compared to the gain when ONC jumps above $20 like Dendreon. Do you have a problem with warning retail investors about a buy side price manipulation? Hold and buy is good advice. Be honest, come out and tell people to sell which is what you are promoting.
24 March Reply
Hey, lightweight (OrdinaryAverageGuy1) read your post again. Your boss will not be impressed by it. I picture you as the new MBA who has joined an investment bank which has a vested interest in pleasing their institutional clients. You did well in your MBA to land the job with the expected yellow brick road to riches. I bet you got an A+ in your ethics course. Too bad, you do not have any. You also may not last in your position.
As for one of your first assignments, you are not doing well posting on this Board. Your first mistake was using the investment bank’s system so the Stockhouse’s system recognized you as a pro and granted a starting reputation rating of 1. You are a cocky SOB and used the firms’ insider information to increase the rating to 2 by adding a performance rating of 1. Since Feb 24, you have made 35 posts with a total number of hits of 5,142. Averaging under 150 hits per post hardly justifies a reputation rating of 2, particularly when they are all personal attacks against me. I’m flattered that your boss is so concerned about my message to retail investors to buy and hold that he assigned you to the case. You are not getting the job done.
Thank you for your concerns about my health. I do not find the status of my health material to a discussion board on investments. If you must know, I’m the picture of good health. The point regarding dying of cancer is that Reolysin will not be a discretionary purchase. The state of the global economy and international events will have negligible impact on Reolysin’s sales volumes. Do you think Michael Douglas’ wealth and name got him access to a Reolysin trial? What straw is Steve Jobs reaching for? Cancer is a cruel disease that can attack anyone.
As for my personal finances and margin calls, they are none of your business. I will leave you with a quiz and a question. ONC opened 2010 at $2.75 and closed the year at $6.73. If I had owned 10,000 shares, I would have made $39,800. The quiz is how many shares did I own last year and how much did I make. Was it under $50,000, $50,000 - $100,000, $100,000 – 250,000, $250,000 - $500,000, $500,000 - $1,000,000, or over $1,000,000? The question is that Oncolytics having the potential to pass $25 a share, why should I hold mutual funds over ONC?